Genoma Group

What Genoma Group does

Eurofins Genoma Group Srl a socio unico ("Genoma Group") is an Italy-based specialty diagnostics laboratory founded in 1997 and operating as a wholly-owned subsidiary of Eurofins Scientific since July 2017. The company is headquartered in Rome with additional operational sites in Milan, Florence, Modena, Bologna, and Forlì, covering more than 4,000 m² of laboratory infrastructure. Its core business is genetic, cytogenetic, and molecular diagnostic testing across more than 25 specialized areas, spanning prenatal diagnosis, oncology, reproductive health, cardiovascular genetics, neurology, andrology, pharmacogenetics, nutrigenetics, and rare-disease panels. The company performs over 250,000 genetic tests annually and offers a catalogue exceeding 3,000 tests, with branded flagship products including PrenatalSafe (non-invasive prenatal screening for chromosomal anomalies), GeneSafe (non-invasive prenatal screening for fetal DNA mutations), GeneScreen (hereditary disease screening), OncoNext (germline and somatic oncology testing) and NutriNext (nutrigenetic predisposition). Underlying methodologies are Next Generation Sequencing (NGS) panels, Multiplex Ligation-dependent Probe Amplification (MLPA), and other molecular biology techniques, with several assays held under CE-IVD in vitro diagnostic marking.

The business model is a professional-services diagnostic testing revenue stream delivered through a hybrid channel: B2B referrals from over 2,000 Italian and foreign healthcare facilities that ship biological samples using UN3373-compliant kit logistics to Genoma laboratories, complemented by a direct-to-consumer pathway where patients book appointments at laboratories or request sampling kits through referring specialists. Reports are delivered through an online portal to ordering physicians. Genoma holds multiple regulatory accreditations issued by ACCREDIA (Italy's national accreditation body) under UNI EN ISO 15189:2024 (Medical Genetics), UNI CEI EN ISO/IEC 17025:2018 (Forensic Genetics, Milan site), and UNI EN ISO 9001:2015, as well as regional SMeL accreditation from the Lombardy Region since 2018. Its headcount exceeds 100 professionals including geneticists, molecular biologists, gynecologists, researchers and laboratory technicians. Public revenue is not disclosed; financial profile is reported within Eurofins Scientific's consolidated specialty diagnostics segment. Recent strategic activity has been funded primarily through two 2020 public grants (LIFE2020 ONCONEXT in oncology and the Ge.Noma Export project targeting extra-national markets) and ongoing geographic expansion of laboratory sites in Emilia-Romagna.

Name

Genoma Group

Legal name

EUROFINS Genoma Group Srl a socio unico

Website

https://laboratoriogenoma.eu

Company type

Private

Founded year

1997

Operating status

Operating

Headcount range

101–250 employees

Short description

Eurofins Genoma Group is an Italy-based specialty molecular diagnostics laboratory, wholly-owned by Eurofins Scientific since 2017, performing over 250,000 genetic, cytogenetic and molecular tests annually across 25+ areas for more than 2,000 healthcare facilities and patients via six Italian laboratory sites.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Genetic testing
• Molecular diagnostics
• Prenatal screening
• Cytogenetic analysis
• Clinical laboratory services

Headquarters

HQ city

Milan

HQ country

Italy

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Laboratory Diagnostic Testing Services: Eurofins Genoma generates revenue through providing genetic, cytogenetic, and molecular diagnostic testing services to healthcare facilities, hospitals, and directly to patients. Over 250,000 genetic tests are performed annually. Tests are processed at company laboratories in Rome, Milan, and Florence, with results delivered to ordering physicians or patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Genoma Group runs a high-throughput human genetics reference laboratory that performs cytogenetic, molecular cytogenetic, and molecular genetic analyses on patient samples, with a catalog of 3,000+ tests spanning 25+ specialty areas including prenatal screening, hereditary cancer, nutrigenomics, and rare disease panels. The lab executes 250,000+ tests per year for 2,000+ Italian healthcare facilities and, via acquisition by Eurofins Scientific in 2017, also supports international pharma and biotech diagnostic work.

Product overview

Genoma Group operates as a molecular diagnostics laboratory offering over 3,000 genetic tests across 25+ specialized areas. The core product portfolio includes five main branded test offerings: PrenatalSafe (non-invasive prenatal testing for chromosomal anomalies), GeneSafe (NIPT for fetal DNA mutations), GeneScreen (hereditary genetic disease screening), NutriNext (food intolerance and diet-related pathology predisposition testing), and OncoNext (germline and somatic mutation identification). These are complemented by specialized diagnostic tests including cystic fibrosis panels (139 and 152 mutation variants, CFTR whole gene sequencing), GExome Clinical and Proband (exome sequencing), and various single-gene and multi-gene panels covering conditions from primary ciliary dyskinesia to tuberous sclerosis. The company also provides laboratory service offerings across clinical cytogenetics and molecular diagnostics.

Differentiator

Problem solved

Functional benefit

Brands

• PrenatalSafe: Non-invasive prenatal test (NIPT) for studying chromosomal anomalies by analyzing fetal DNA circulating in maternal blood.
• GeneSafe
• GeneScreen
• NutriNext
• OncoNext

Products and services

• PrenatalSafe Non-invasive prenatal test (NIPT) for fetal chromosomal abnormality screening from maternal blood, available to pregnant women either through their clinician or via direct-to-patient order.
• GeneSafe Hereditary cancer genetic test panel assessing predisposition to inherited cancer syndromes, offered to individuals via clinicians or direct patient order.
• GeneScreen Genetic screening panel for carrier status and inherited conditions, including newborn and reproductive carrier screening, available to clinicians and patients.
• NutriNext Nutrigenomics test providing DNA-based insights into personalized nutritional and metabolic responses, sold to consumers directly or via clinicians and wellness professionals.
• OncoNext Clinical next-generation sequencing oncogenetics panel used for hereditary cancer risk evaluation and tumor profiling indications.
• CF Panel (Cystic Fibrosis testing) Molecular test for cystic fibrosis mutation analysis, used for carrier screening and diagnostic confirmation by clinicians and reproductive specialists.
• GExome (clinical whole-exome sequencing) Clinical whole-exome sequencing service for rare disease and undiagnosed genetic disorder cases, typically ordered by hospital geneticists.
• Cytogenetic and molecular cytogenetic analyses (karyotype, FISH, MLPA) Reference-laboratory cytogenetic and molecular cytogenetic services (karyotyping, FISH, and MLPA-based copy-number analysis) performed on patient samples for clinicians and hospitals.
• Pharma/biotech genetic testing services Specialized genetic testing capacity and assay development sold to pharmaceutical, biotech, and clinical-research sponsors for clinical trials and biomarker work.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered minor and core.

• Italian Pharmaceutical CompaniesminorStrategic or Co-development PartnerSeveral projects have been initiated in Italy with pharmaceutical companies, with the aim of offering a valid genetic tool to support diagnosis and drug development. The collaboration focuses on providing genetic diagnostic support for pharmaceutical research and development programs.
• Major Oncological Centers (Regional and National)coreStrategic or Co-development PartnerEurofins Genoma operates through a network of scientific collaborations with major oncological centers present in the regional and national scope, as part of the LIFE2020 ONCONEXT funded project. The company responds to growing public and private demands through the use of advanced and validated technologies.
• ACCREDIAcoreOthersACCREDIA is the Italian national accreditation body. Eurofins Genoma has a convention with ACCREDIA defining mutual obligations; maintaining accreditation involves periodic assessment by ACCREDIA of the technical and managerial competence of the laboratory in compliance with UNI EN ISO 15189:2024 requirements and additional ACCREDIA requirements.

Scale indicators7 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Synlab Italia: Italy's largest medical diagnostics network offering clinical and specialty lab testing including genetic diagnostics across hospitals and patients. Direct competitor of Eurofins Genoma for hospital channel and DTC genetic-testing volume in Italy.
• Natera: US-based specialty molecular diagnostics company with leading NIPT and oncology genomics products (e.g., Panorama, Empower). Direct competitive overlap with Genoma's PrenatalSafe NIPT and OncoNext lines.
• Centogene: Germany-based rare disease and genetic diagnostics laboratory serving hospitals globally with multi-gene panels, exome sequencing and biomarker services. Closely comparable to Genoma's panel/multi-gene NGS business model.
• GeneDx (Sema4): Clinical genomics laboratory offering exome/genome sequencing and rare-disease panels to physicians and hospitals worldwide. Comparable product mix (clinical exome, multi-gene panels) and channel (B2B referral).
• Cerba Healthcare Italia: European specialty diagnostics provider with strong Italian presence offering advanced genetic and molecular testing to hospitals and clinicians. Competes head-to-head with Genoma for specialty genetic-test referrals.
• Eurofins Medigenoma: Sister Eurofins lab in Germany providing human genetics and reproductive diagnostics. Sister-subsidiary overlap that competes with Genoma across the shared Eurofins pan-European client base.
• Invitae: US clinical genetic testing company offering comprehensive panels across hereditary cancer, rare disease, reproductive health and pharmacogenomics to hospitals and physicians. Direct comparable in product breadth, menu depth and B2B channel.

Broad incumbents

• Myriad Genetics: Established US genetic testing company offering hereditary cancer, NIPT and pharmacogenomics panels to clinicians. Overlaps with Genoma's OncoNext and pharmacogenetics offerings at a global scale.

Regional players

• Medicover Genetics: Central/Eastern European diagnostics and genetics operator offering NIPT and hereditary testing to physicians. Comparable genetic-testing service portfolio, mostly overlapping regional footprints.

Emerging players

• Breda Genetics: Italian/European boutique genetics lab focused on rare-disease panels and prenatal diagnostics for clinicians. Direct product overlap in NIPT and rare-disease panels, smaller scale than Genoma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/LaboratorioGenoma
• LinkedInlinkedin.com/company/genoma-srl

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genoma Group